The Technical Analyst
Xenon Pharmaceuticals Inc [XENE]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Xenon Pharmaceuticals Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-3.17% $40.31
America/New_York / 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 3 040.68 mill |
| EPS: | -2.73 |
| P/E: | -14.77 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 75.43 mill |
| Avg Daily Volume: | 0.364 mill |
| RATING 2024-04-18 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | |||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -14.77 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -2.51x |
| Company: PE -14.77 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$2.06 (-94.89%) $-38.25 |
| Date: 2024-04-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 38.73 - 41.89 ( +/- 3.92%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-11 | Von Seggern Christopher | Buy | 100 000 | Stock Option (Right to Buy) |
| 2024-03-11 | Aulin Sherry | Buy | 100 000 | Stock Option (Right to Buy) |
| 2024-03-11 | Kenney Christopher John | Buy | 100 000 | Stock Option (Right to Buy) |
| 2024-03-11 | Empfield James R. | Buy | 65 000 | Stock Option (Right to Buy) |
| 2024-03-11 | Robin Sherrington | Buy | 65 000 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 59.25 |
| Last 100 transactions |
| Buy: 2 181 840 | Sell: 619 411 |
Forecast:
16:00 - $40.38
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $40.38
Forecast 2: 16:00 - $40.38
Forecast 3: 16:00 - $40.38
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $40.31 (-3.17% ) |
| Volume | 0.313 mill |
| Avg. Vol. | 0.364 mill |
| % of Avg. Vol | 85.93 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For XENE
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:32 | sell | $47.92 | N/A | Active |
|---|
XENE
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Last 10 Buy Signals
Latest Press Releases
2024-04-16 08:30:00 - Press Release
Xenon Pharmaceuticals Showcases Xen1101 At The American Academy Of Neurology 2024 Annual Meeting
Vancouver, british columbia, april 16, 2024 (globe newswire) -- xenon pharmaceuticals inc. (nasdaq:xene), a neuroscience-focused biopharmaceutical company, announced two oral presentations highlighting xen1101 clinical data at the american academy of neurology (aan) 2024 annual meeting in denver, co.
2024-04-10 08:30:00 - Press Release
Xenon Pharmaceuticals To Present At The 2024 Bloom Burton & Co. Healthcare Investor Conference
Vancouver, british columbia, april 10, 2024 (globe newswire) -- xenon pharmaceuticals inc. (nasdaq:xene), a neurology-focused biopharmaceutical company, today announced that the company will present at the 2024 bloom burton & co. healthcare investor conference taking place april 16-17, 2024.
2024-04-04 16:01:00 - Press Release
Xenon Pharmaceuticals To Present At The 23rd Annual Needham Virtual Healthcare Conference
Vancouver, british columbia, april 04, 2024 (globe newswire) -- xenon pharmaceuticals inc. (nasdaq:xene), a neurology-focused biopharmaceutical company, today announced that the company will present at the 23rd annual needham (virtual) healthcare conference taking place april 8-11, 2024.
2024-03-12 16:01:00 - Press Release
Xenon Pharmaceuticals To Present At Stifel 2024 Virtual Cns Days
Vancouver, british columbia, march 12, 2024 (globe newswire) -- xenon pharmaceuticals inc. (nasdaq:xene), a neurology-focused biopharmaceutical company, today announced that the company will present at the stifel 2024 virtual cns days event.
2024-03-05 16:01:00 - Press Release
Xenon Pharmaceuticals To Present At Leerink Partners Global Biopharma Conference 2024
Vancouver, british columbia, march 05, 2024 (globe newswire) -- xenon pharmaceuticals inc. (nasdaq:xene), a neurology-focused biopharmaceutical company, today announced that the company will present at leerink partners global biopharma conference 2024 to be held in miami, fl on march 11-13, 2024.
Latest News
2024-04-10 08:30:00 - GlobeNewsWire
Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
VANCOUVER, British Columbia, April 10, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the 2024 Bloom Burton & Co. Healthcare Investor Conference taking place April 16-17, 2024.
2024-04-04 16:01:00 - GlobeNewsWire
Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference
VANCOUVER, British Columbia, April 04, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the 23rd Annual Needham (Virtual) Healthcare Conference taking place April 8-11, 2024.
2024-03-01 09:36:03 - Zacks Investment Research
Xenon (XENE) Q4 Earnings Top Estimates, Pipeline in Focus
Xenon (XENE) reports mixed fourth-quarter 2023 financial results, wherein earnings beat estimates but revenues missed the same. Its development programs for XEN1101 in epilepsy and MDD are progressing well.
2024-02-21 22:08:19 - InvestorPlace
3 Biotech Stocks That Could Be Multibaggers in the Making: February Edition
Now that the FED is looking to lower interest rates this year, cheaper money and more accessible financing will let investors venture into riskier places in the economy and the stock market. While not that risky of an industry, the biotech space can often be speculative.
2024-01-23 09:41:20 - Zacks Investment Research
Here's Why You Should Add Xenon (XENE) to Your Portfolio Now
Xenon's (XENE) late-stage studies in epilepsy are progressing well. The company is also gearing up to initiate a late-stage study for the MDD indication in 2024.
2024-01-19 10:56:34 - Zacks Investment Research
Wall Street Analysts Think Xenon Pharmaceuticals (XENE) Could Surge 25.76%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 25.8% in Xenon Pharmaceuticals (XENE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
2024-01-03 08:30:00 - GlobeNewsWire
Xenon Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
VANCOUVER, British Columbia, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the 42nd Annual J.P. Morgan Healthcare Conference taking place in San Francisco, CA from January 8-11, 2024.
2023-12-07 15:00:00 - Seeking Alpha
Rare Stock Picks In November 2023 - From 31 Discerning Analysts
Welcome to another installment of our monthly Rare Stock Picks series. Today we're highlighting November 2023 investment picks you may have missed. As you know, some Seeking Alpha analysts are more discerning by nature. Others are finding compelling ideas hard to come by in today's market environment. Featured in this series are investment ideas published in the last month from analysts who have made ONLY 1 Buy/Strong Buy stock recommendation in the past three months.
2023-11-28 12:47:22 - Zacks Investment Research
Xenon (XENE) Up on Top-Line Data From MDD Drug Phase II Study
Xenon (XENE) posts top-line data from a phase II proof-of-concept study evaluating its pipeline candidate, XEN1101, for treating moderate-to-severe major depressive disorder. Stock rises.
2023-11-27 12:05:11 - Proactive Investors
Xenon Pharma depression drug fails to meet study goal but analysts see positives
Xenon Pharma shares moved higher on Monday despite the Vancouver, British Columbia neurology-focused biopharmaceutical company reporting that its investigational therapeutic for major depressive disorder (MDD) failed to meet the primary endpoint of a Phase 2 study. The study evaluated the efficacy, safety and tolerability of 10 mg and 20 mg of XEN1101 in patients with MDD.